RASSF5 and rhabdomyosarcoma: Notably, inhibition of YAP1 by dasatinib in the context of rhabdomyosarcoma is only successful in combination with DNA methyltransferase inhibitors (DNMTi) that upregulate RASSF1 and RASSF5 by promoter demethylation, resulting in the activation of canonical Hippo signaling and the inactivation of YAP1 by phosphorylation [46].